Use of urolithin derivatives in the treatment of amyotrophic lateral sclerosis (ALS)

Urolithin derivatives are administered to treat ALS, targeting mitochondrial dysfunction to provide improved therapeutic outcomes beyond current treatments, addressing the limitations of existing ALS therapies.

JP2026522177APending Publication Date: 2026-07-07VANDRIA SA
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
VANDRIA SA
Filing Date
2024-05-17
Publication Date
2026-07-07

AI Technical Summary

Technical Problem

Current treatments for amyotrophic lateral sclerosis (ALS), particularly C9orf72 amyotrophic lateral sclerosis (C9-ALS), are inadequate, with the FDA-approved drug riluzole only extending survival by approximately 10%, highlighting the need for more effective therapeutic options.

Method used

Administering specific urolithin derivatives, such as compounds of formula (Ia), (Ic), (Id), (Ie), (If), (Ih), (IIa), or (IIb), to subjects in need of treatment for ALS, including C9-ALS, to address the underlying mitochondrial dysfunction associated with the condition.

Benefits of technology

The urolithin derivatives demonstrate potential in significantly improving muscle function and potentially offering more effective treatment options for ALS, beyond the limited benefits of existing therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026522177000001
    Figure 2026522177000001
  • Figure 2026522177000002
    Figure 2026522177000002
  • Figure 2026522177000003
    Figure 2026522177000003
Patent Text Reader

Abstract

A method for treating amyotrophic lateral sclerosis (ALS) has been disclosed. Furthermore, a method for treating C9orf72 amyotrophic lateral sclerosis (C9-ALS) has also been disclosed.
Need to check novelty before this filing date? Find Prior Art